Skip to content
TARSTarsus Pharmaceuticals, Inc.

Earnings

When Tarsus Pharmaceuticals, Inc. reports, what it reported each quarter, and how the stock took the results.

31 quarters. Mar 31, 2019 to Sep 30, 2026. USD.

Next results · Q4 2026Projected

Feb 22, after the close

Mon, Feb 22, 2027in 96 days

Projected from its last 8 releases. The company has not named the day yet.

Quarter
Q4 2026 · Ends about Dec 31, 2026
10-K window
Feb 22 – Mar 19

Read against Q4 2025

The same quarter a year earlier, the figures the next ones will be compared with. Thaler holds no estimates.

Revenue
$151.67M
Revenue, change from a year earlier: Q3 2026 +63.9%, Q2 2026 +69.4%, Q1 2026 +106.9%, Q4 2025 +128.4%
Net income
-$8.37M
Net income, change from a year earlier: Q3 2026 n/m, Q2 2026 n/m, Q1 2026 n/m, Q4 2025 n/m
EPS
—
EPS, change from a year earlier: Q3 2026 n/m, Q2 2026 n/m, Q1 2026 n/m, Q3 2025 n/m

Quarter by quarter

Q3 2026$194.57M+63.9% vs Q3 2025

Latest results

  1. Q3 2026Nov 3, 2026, after the closeThe release4.7%by the close of Nov 4
    Revenue
    $194.57M
    +63.9%
    Net income
    -$668.33M
    N/M
    EPS
    -$14.40
    N/M
    Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) today announced financial results for the third quarter ended September 30, 2026.
  2. Q2 2026Aug 5, 2026, after the closeThe release+6.7%by the close of Aug 6
    Revenue
    $173.91M
    +69.4%
    Net income
    -$18.55M
    N/M
    EPS
    -$0.43
    N/M
  3. Q1 2026May 6, 2026, after the closeThe release1.1%by the close of May 7
    Revenue
    $162.05M
    +106.9%
    Net income
    -$6.97M
    N/M
    EPS
    -$0.16
    N/M
  4. Q4 2025Feb 23, 2026, after the closeThe release+7.8%by the close of Feb 24
    Revenue
    $151.67M
    +128.4%
    Net income
    -$8.37M
    N/M
    EPS
    —
    —

All quarters

PeriodEndedAnnouncedFiledLagFormRevenueΔ yoyEPS dil.MoveSource trail
FY 2026
Q3 2026Sep 30, 2026Nov 3, 2026 · after-hoursNov 3, 202634 d10-Q$194.57M+63.9%-$14.404.7%
Q2 2026Jun 30, 2026Aug 5, 2026 · after-hoursAug 6, 202637 d10-Q$173.91M+69.4%-$0.43+6.7%
Q1 2026Mar 31, 2026May 6, 2026 · after-hoursMay 6, 202636 d10-Q$162.05M+106.9%-$0.161.1%
FY 2025
Q4 2025derivedDec 31, 2025Feb 23, 2026 · after-hoursFeb 23, 202654 d10-K$151.67M+128.4%—+7.8%
Q3 2025Sep 30, 2025Nov 4, 2025 · after-hoursNov 4, 202535 d10-Q$118.70M+146.7%-$0.304.7%
Q2 2025Jun 30, 2025Aug 6, 2025 · after-hoursAug 6, 202537 d10-Q$102.66M+151.5%-$0.48+15.0%
Q1 2025Mar 31, 2025May 1, 2025 · after-hoursMay 1, 202531 d10-Q$78.34M+183.7%-$0.645.6%
FY 2024
Q4 2024derivedDec 31, 2024Feb 24, 2025 · after-hoursFeb 25, 202556 d10-K$66.41M+407.9%—9.3%
Q3 2024Sep 30, 2024Nov 13, 2024 · after-hoursNov 13, 202444 d10-Q$48.12M+2,471.8%-$0.61+0.2%
Q2 2024Jun 30, 2024Aug 8, 2024 · after-hoursAug 8, 202439 d10-Q$40.81M—-$0.88—
Q1 2024Mar 31, 2024May 8, 2024 · after-hoursMay 8, 202438 d10-Q$27.61M+1,004.6%-$1.01—
Earlier years, FY 2019 to FY 2023

Move: the stock from the last close before the release to the first close after it. Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

Source filings

10-QNov 3, 2026000076
10-QAug 6, 2026000064
10-QMay 6, 2026000038
10-KFeb 23, 2026000019
10-QNov 4, 2025000121
10-QAug 6, 2025000108
10-QMay 1, 2025000078
10-KFeb 25, 2025000011
10-QNov 13, 2024000129
10-QAug 8, 2024000111

Provenance

ProvenanceData status and checks

Tarsus Pharmaceuticals, Inc. · CIK 1819790 · Engraved from SEC EDGAR